

## Publikationsverzeichnis (Stand 01/12)

### Prof. Dr. med. Cornelia Gelbmann

#### A: *Originalarbeiten*

1. **Gelbmann CM**, Müller WE.  
Specific decrease of high-affinity agonist states of alpha 2-adrenoceptors in the aging mouse brain.  
*J. Neural. Transm. Gen. Sect.* 1990;79:131-136.
2. **Gelbmann CM**, Müller WE.  
Chronic treatment with phosphatidylserine restores muscarinic cholinergic receptor deficits in the aged mouse brain.  
*Neurobiol. Aging* 1992;13: 45-50.
3. **Gelbmann CM**, Schteingart CD, Thompson SM, Hofmann AF, Barrett KE.  
Mast cells and histamine contribute to bile acid-stimulated secretion in the mouse colon.  
*J Clin Invest* 1995; 95:2831-2839.
4. **Gelbmann CM**, Barrett KE.  
Role of histamine in a rat model of colitis.  
*Inflamm Res* 1995; 44: 386-392.
5. Uribe JM, **Gelbmann CM**, Traynor-Kaplan AE, Barrett KE.  
Epidermal growth factor inhibits  $\text{Ca}^{2+}$ -dependent  $\text{Cl}^-$  transport in T84 human colonic epithelial cells.  
*Am J Physiol* 1996;271: C914-C922.
6. **Gelbmann CM**, Mestermann S, Gross V, Köllinger M, Schölmerich J, Falk W.  
Strictures in Crohn's disease are characterized by an accumulation of mast cells colocalized with laminin but not with fibronectin or vitronectin.  
*Gut* 1999;45:210-217.
7. Lock G, Knöll A, Hauer S, **Gelbmann CM**, Hellerbrand C, Jilg W, Schölmerich J, Hartmann A.  
Leberhistologie bei Hepatitis C: Korrelation mit verschiedenen biochemischen und virologischen Parametern.  
*Med Klin* 2000, 95:603-607.
8. Rogler G, **Gelbmann CM**, Vogl D, Brunner M, Schölmerich J, Falk W, Andus T, Brand K.  
Differential activation of cytokine secretion in primary human colonic fibroblast/myofibroblast cultures.  
*Scan J Gastroenterol* 2001;36:389-398.
9. Braaden B, **Gelbmann CM**, Dietrich CF, Caspary WF, Schölmerich J, Lock G.  
Qualitative and quantitative clinical evaluation of the laser-assisted ratio analyser of Helicobacter pylori infection by (13)C-urea breath tests.  
*Eur J Gastroenterol Hepatol* 2001;13:807-810.

10. Schlottmann K, **Gelbmann CM**, Grüne S, Lock G, Schölmerich J.  
Eine neue Parazentesenadel für Aszites und Pleuraerguss im Vergleich mit der Venenverweilkanüle – Eine prospektive, randomisierte Studie.  
*Med Klin* 2001;96:321-324.
11. **Gelbmann CM**, Rogler G, Gierend M, Gross V, Schölmerich J, Andus T.  
Association of HLA-DR genotypes and IL-1ra gene polymorphism with treatment failure to budesonide and disease patterns in Crohn's disease.  
*Eur J Gastroenterol Hepatol* 2001;13:1431-1437.
12. **Gelbmann CM**, Rogler G, Gierend M, Bregenzer N, Gross V, Andus T und Schölmerich J.  
Prior bowel resections, perianal disease, and a high initial Crohn's disease activity index are associated with corticosteroid resistance in active Crohn's disease.  
*Am J Gastroenterol* 2002;97:1438-1445.
13. Leeb SN, Vogl D, Falk W, Schölmerich J, Rogler G, **Gelbmann CM**.  
Regulation of migration of human colonic myofibroblasts.  
*Growth Factors* 2002;20:81-91.
14. Bregenzer N, Soldner M, **Gelbmann CM**, Vogt T, Schölmerich J, Andus T.  
Value of abdominal ultrasound screening in patients with benign diseases of the skin.  
*Dtsch Med Wochenschr* 2003;128:1699-1702.
15. Rogler G, **Gelbmann CM**, Leeb SN, Vogl D, Brunner M, Herfarth H, Schölmerich J, Falk W.  
Inducible CD40 expression mediates NF-κB activation and cytokine secretion in human colonic myofibroblasts.  
*Gut* 2003;52:1448-1456.
16. Leeb SN, Vogl D, Gunckel M, Kiessling S, Falk W, Schölmerich J, **Gelbmann CM**, Rogler G (gleichberechtigte Letztautorschaft).  
Reduced migration of fibroblasts in inflammatory bowel disease: role of inflammatory mediators and focal adhesion kinase.  
*Gastroenterology* 2003;125:1341-1354.
17. Klebl FH, **Gelbmann CM**, Lammert I, Bogenrieder T, Stolz W, Schölmerich J, Schlottmann K.  
Detection of lymph node metastases of malignant melanoma by palpation and ultrasound.  
*Med Klin* 2003;98:783-787.
18. Leeb SN, Vogl D, Grossmann J, Falk W, Schölmerich J, Rogler G, **Gelbmann CM**.  
Autocrine fibronectin-induced migration of human colonic fibroblasts.  
*Am J Gastroenterol* 2004;99:335-340.
19. **Gelbmann CM**, Ratiu NL, Rath HC, Rogler G, Lock\* G, Schölmerich J, Kullmann F.  
Use of self-expandable plastic stents for the treatment of esophageal perforations and symptomatic anastomotic leaks.  
*Endoscopy* 2004;36:695-699.

20. Endlicher E, **Gelbmann CM**, Knüchel R, Fürst A, Szeimies RM, Gölder S, Schölmerich J, Lottner C, Messmann H.  
Hexaminolevulinate-induced fluorescence endoscopy in patients with rectal adenoma and cancer – a pilot study.  
*Gastrointestinal Endoscopy* 2004;60:449-454.
21. Mühlbauer M, Weiss TS, Thasler WE, **Gelbmann CM**, Schnabl B, Schölmerich J, Hellerbrand C.  
LPS-mediated NFκB activation varies between activated human hepatic stellate cells from different donors.  
*Biochem Biophys Res Commun* 2004;325:191-197.
22. Ratiu N, Rath HC, Büttner R, **Gelbmann CM**, Klebl F, Kullmann F, Rogler G, Strauch UG, Schölmerich J, Messmann H.  
The effect of chromoendoscopy on the diagnostic improvement of gastric ulcers by endoscopists with different levels of experience.  
*Rom J Gastroenterol* 2005; 14:239-44.
23. Wiegand J, Buggisch P, Boecker W, Zeuzem S, **Gelbmann CM**, Berg T, Kauffmann W, Kallinowski B, Cornberg M, Jaeckel E, Wedemeyer H, Manns MP.  
Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: The HEP-NET acute-HCV-II study.  
*Hepatology* 2006; 43:250-256.
24. Bregenzer N, Schaffler A, **Gelbmann CM**, Steinkamp M, Reinshagen M, Scholmerich J, Andus T. Lack of correlation between the vitamin D receptor FokI start codon polymorphism and bone mineral density in patients with Crohn's disease.  
*Exp Clin Endocrinol Diabetes* 2006;114:1-5.
25. Lock G, Dirscherl M, Obermeier F, **Gelbmann CM**, Hellerbrand C, Knoell A, Schölmerich J, Jilg W.  
Hepatitis C - contamination of toothbrushes: myth or reality?  
*J Viral Hepat* 2006;13:571-3.
26. Ott C, Ratiu N, Endlicher E, Rath HC, **Gelbmann CM**, Schölmerich J, Kullmann F.  
Self-expanding Polyflex plastic stents in esophageal disease: various indications, complications, and outcomes.  
*Surg Endosc*. 2007;21:889-96.
27. **Gelbmann CM**, Rümmele P, Wimmer M, Hofstädter F, Göhlmann B, Endlicher E, Kullmann F, Langgartner J, Schölmerich J.  
Ischemic-like cholangiopathy with secondary sclerosing cholangitis in critically ill patients.  
*Am J Gastroenterol*. 2007;102:1221-9.
28. Ratiu N, **Gelbmann CM**, Rath HR, Herfarth H, Kullmann F, Schölmerich J, Messmann H.  
Chromoendoscopy with indigo carmine in flexible sigmoidoscopy screening: does it improve the detection of adenomas in the distal colon and rectum?  
*J Gastrointest Liver Dis.* 2007;16:153-6.

29. Witthöft T, Möller B, Wiedmann KH, Mauss S, Link R, Lohmeyer J, Lafrenz M, **Gelbmann CM**, Hüppe D, Niederau C, Alshuth U.  
Safety, tolerability and efficacy of peginterferon alpha-2a and ribavirin in chronic hepatitis C in clinical practice: The German Open Safety Trial.  
*J Viral Hepat.* 2007;14:788-96.
30. Factors affecting cecal and ileal intubation time in colonoscopy.  
Zuber-Jerger I, Endlicher E, **Gelbmann CM**.  
*Med Klin (Munich).* 2008;103:477-81
31. Zuber-Jerger I, Endlicher E, Kullmann F, **Gelbmann CM**.  
A new grading system to evaluate the risk of endoscopic retrograde cholangio-pancreatography.  
*J Gastroenterol* 2009;44:160-5
32. Endlicher E, **Gelbmann CM**, Messmann H.  
Reflux disease and Barrett's oesophagus – are there gender specific differences.  
*Z Gastroenterol* 2009;47:1065-8
33. Zuber-Jerger I, Müller A, Kullmann F, **Gelbmann CM**, Endlicher E, Müller-Ladner U, Fleck M.  
Gastrointestinal manifestation of systemic sclerosis--thickening of the upper gastrointestinal wall detected by endoscopic ultrasound is a valid sign.  
*Rheumatology* 2010;49:368-72.
34. Siebig S, Meinel A, Rogler G, Klebl E, Wrede CE, **Gelbmann C**, Froh S, Rockmann F, Bruennler T, Schoelmerich J, Langgartner J.  
Decreased cytosolic glucocorticoid receptorlevels in critically ill patients  
*Anaesth Intensive Care* 2010;38:133-40
35. Buti M, Lurie Y, Zakharova NG, Blokhina NP, Horban A, Teuber G, Sarrazin C, Balciuniene L, Feinman SV, Faruqi R, Pedicone LD, Esteban R; SUCCESS Study Investigators.  
Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response  
*Hepatology* 2010;52:1201-7
36. Kirchner GI, Scherer MN, Obed A, Ruemmele P, Wiest R, Froh M, Loss M, Schlitt HJ, Schölmerich J, Gelbmann CM.  
Outcome of patients with ischemic-like cholangiopathy with secondary sclerosing cholangitis after liver transplantation  
*Scand J Gastroenterol* 2011;46:471-8
37. Lippert E, Klebl FH, Schweller F, Ott C, Gelbmann CM, Schölmerich J, Endlicher E, Kullmann F.  
Fibrin glue in the endoscopic treatment of fistulae and anastomotic leakages of the gastrointestinal tract  
*Int J Colorectal Dis.* 2011;26:303-11
38. Kirchner GI, Zuber-Jerger I, Endlicher E, **Gelbmann C**, Ott C, Ruemmele P, Schölmerich J, Klebl F.  
Causes of bolus impaction in the esophagus  
*Surg Endosc* 2011;25):3170-4

## B: Übersichten

1. Müller WE, Stoll L, Schubert T, **Gelbmann CM**. Central cholinergic functioning and aging. *Acta Psychiatr. Scand. Suppl.* 1991;366:34-39.
2. Köllinger M, **Gelbmann CM**, Holstege A. Leberfibrose: neue Ansätze zur Therapie. *Arzneimitteltherapie* 1996; 9: 266-271.
3. Bregenzer N, Lock G, **Gelbmann C**, Schölmerich J. Diagnostik und Therapie der akuten Oberbauchkolik. *Notfall Medizin* 1998; 2: 70-77.
4. **Gelbmann CM**  
Prediction of treatment refractoriness in ulcerative colitis and Crohn's disease--do we have reliable markers?  
*Inflamm Bowel Dis* 2000; 6:123-131.
5. Messmann H, Endlicher E, **Gelbmann CM**, Schölmerich J. Fluorescence endoscopy and photodynamic therapy. *Digest Liver Dis* 2002;34:754-761
6. **Gelbmann CM**  
Der komplizierte, chronische Verlauf der Hepatitis B, wie lange behandeln?  
XXXI. Kongress der Gesellschaft für Gastroenterologie in Bayern,  
*Z Gastroenterol, Beilage* Juni 2003
7. **Gelbmann CM**  
Hepatotoxische Nebenwirkungen von Psychopharmaka  
*Neurotransmitter* ; Dezember 2006
8. **Gelbmann CM**, Jürgen Schölmerich  
Sekundär sklerosierende Cholangitis bei Intensivpatienten – ein neues Krankheitsbild?  
*Der Gastroenterologe* ; Januar 2008
9. Ruemmele P, Hofstaedter F, **Gelbmann CM**  
Secondary Sclerosing Cholangitis.  
*Nat Rev Gastroenterol Hepato.* 2009;5:287-95
10. Gelbmann CM, Melter M.  
Chronically ill children become grown-up. What does the internist learn from the pediatrician?  
*Internist (Berl)*. 2010 Apr;51(4):482-8. German.

## C: Buchkapitel

1. Müller WE, **Gelbmann CM**, Pilch H. The restoration of age-related receptor deficits, a common mechanism of nootropic activity? In: *Pharmacology of Central Ischemia*. J. Kriegelstein (ed.) WVG, Stuttgart, 1988, pp. 353-358.

2. Müller WE, **Gelbmann CM**, Cohen SA, Stoll L.  
Age-associated changes of muscarinic cholinergic and N-methyl-D-aspartate receptors in the mouse brain. Partial reconstitution by phosphatidylserine treatment. In: *Biology of Aging*. C. Balduini and R. Zwilling (eds.) Springer, Heidelberg, 1992, pp: 17-27.
3. **Gelbmann CM**, Barrett KE.  
Role of inflammatory cell types. In: *Inflammatory Bowel Diseases - Pathophysiology as Basis of Treatment*. J Schölmerich, W Kruis, H Goebell, W Hohenberger and V Gross, Editors, Kluwer Academic, Lancaster, UK, 1993, pp 62-79.
4. **Gelbmann CM**, Barrett KE.  
In vitro models of epithelial pathophysiology. In: *Experimental Models of Mucosal Ulceration and Inflammation*, TS Gaginella, Editor, CRC Press, 1996, pp 111-131.

#### D: **Fallberichte , Editorials**

1. **Gelbmann CM**, Barrett KE.  
Editorial: Neuroimmune regulation of human intestinal transport (editorial).  
*Gastroenterology* 1993;105: 934-936.
2. **Gelbmann CM**, Köllinger M, Gmeinwieser J, Leser HG, Holstege A, Schölmerich J.  
Spontaneous rupture of the liver in a patient with Ehlers Danlos disease type IV.  
*Dig. Dis Sci* 1997; 42:1724-1730.
3. Bregenzer N, Lock G, **Gelbmann CM**, Schölmerich J.  
Diagnose: Caroli-Syndrom.  
*Notfall Medizin* 1998; 2:78-79.
4. Schlottmann K, **Gelbmann CM**, Schölmerich J, Lock G.  
Die interkostal angelegte perkutane ultraschallgesteuerte Entlastungsgastrostomie (PUG) – Ein Fallbericht.  
*Ultraschall in Med* 2000; 21:1-3.
5. Endlicher E, **Gelbmann CM**, Schlottmann K, Herfarth H, Rummele P, Friedrich A, Schölmerich J, Kullmann F.  
Endoskopische Mukosaresektion eines Ösophagusfrühkarzinoms bei Leberzirrhose und Ösophagusvarizen.  
*Z Gastroenterol* 2004;42:609-13.
6. Rieder F, Hamer O, **Gelbmann CM**, Hellerbrand C, Knoll A, Schölmerich J, Lock G.  
Crohn's disease of the esophagus: treatment of an esophagobronchial fistula with the novel liquid embolic polymer "onyx".  
*Z Gastroenterol* 2006;44:599-602.
7. Schacherer D, Zeitoun M, Buttner R, **Gelbmann CM**, Obed A, Schlitt HJ, Scholmerich J, Kirchner GI.  
Sirolimus-induced drug fever and ciclosporin-induced leukencephalopathy with seizures in one liver transplant recipient.  
*World J Gastroenterol*. 2007;13:6090-3.